It is uncommon for pediatric patients with rhabdomyosarcoma to present with clinical and/or laboratory features of disseminated intravascular coagulation (DIC). We report a case of metastatic alveolar rhab domyosarcoma with severe bleeding because of DIC in a 13yearold boy. He experienced persistent oozing at the site of a previous operation, gross hematuria, and massive epistaxis. Two weeks after initiating combination chemotherapy consisting of vincristine, doxorubicin, and cyclophosphamide, the patients' laboratory indications of DIC began to resolve. During this period, the patient received massive blood transfusion of a total of 311 units (26 units of red blood cells, 26 units of fresh frozen plasma, 74 units of platelet concentrates, 17 units of single donor platelets, and 168 units of cryoprecipitate), anti thrombinIII and a synthetic protease inhibitor. Despite chemotherapy and radiation therapy, he died 1 year later because of disease progression. In children with metastatic rhabdomyosarcoma and massive DIC, prompt chemotherapy and aggressive supportive care is important to decrease malignancytrig gered procoagulant activities.
Introduction
Disseminated intravascular coagulation (DIC) is a systemic thrombohemorrhagic disorder with variable pathophysiology. The underlying diseases causing DIC include obstetric acci dents, intravascular hemolysis, septicemia, viremia, burns, trauma, acute liver disease, and malignant disease 1) . There is a causal relationship between DIC and the presence of malig nancy 2) . The incidence of DIC was reported on 7% of the patients with solid tumor and 15%-20% of the patients with acute leukemia 3, 4) . DIC in pediatric solid tumor has been reported with disseminated neuroblastoma, nephroblastoma, infantile fibrosarcoma, and multisystem Langerhans cell histiocytosis 5) . The pediatric patients with rhabdomyosarcoma presenting with DIC at diagnosis are rare and are mainly seen with the widespread alveolar rhabdo myosarcoma metastatic to bone marrow (BM) 3) . Clinically, DIC in cancer is less fulminant than the types of DIC seen in sepsis and trauma. Also, chronic and systemic activation of coagulation can progress subclinically, and this progression may lead to exhaustion of coa gulation factors and platelets. Therefore, bleeding may be the first clinical symptom of DIC in a patient with cancer 2) . Here, we describe an unusual case with acute bleeding and DIC, which were severe and very difficult to control, with the presenting manifestation of alveolar rhabdomyosarcoma metastatic to BM. Early administration of chemotherapy and vigorous supportive care could control the massive bleeding and DIC.
Case report
A 13yearold boy was admitted in January 2011, due to an uncontrolled bleeding at the operation site of the right thenar muscle. The swelling of the right thenar muscle developed after a fall on August 2010 (Fig. 1A, B) . However, no treatment was given under the impression that the swelling was a hematoma. After showing no improvement for over 5 months, excision of this lesion was attempted at a private orthopedic surgery clinic. Before marginal excision, the patient had no history of bleeding tendency and normal coagulation screening tests. He underwent two addi tional operations at different hospitals for the control of bleeding, but the bleeding at the operation site continued.
When a pathologic finding of the mass suggested a diagnosis of malignancy, he was transferred to our hospital for further ma nagement. At the admission, the patient's general state was poor with signs of pallor, weakness, bruising at the intravenous site, and purpura on the operation site over the right thenar muscle with continuous bleeding (Fig. 1C) . In the physical examination, there was a 2×2 cmsized lymph node (LN) in the right axillary area and 1 cmsized hepatosplenomegaly. Laboratory tests re vealed markedly decreased platelet and hemoglobin levels and features suggestive of DIC (white blood cell, 9,900 /μL; hemoglo bin, 4.8 g/dL; platelets, 28,000 /μL; prothrombin time, 1.47 inter national normalized ratio; activated partial thromboplastin time, 45.4 sec; fibrinogen, 87 mg/dL; fibrin/fibrinogen degeneration product, 656.4 μg/mL; and Ddimer, 16.17 mg/L). The coagulation factors II, VII, IX, fibrinogen, and von willebrand factor were all normal. The factors V and VIII were 30% (normal, 60%-140%) and 40% (normal, 50%-150%), respectively. 18Fluoro2deoxy Dglucose positron emission tomography scan showed hyperme tabolic lesions (maximum standardized uptake value [SUVmax], 2.7) along the rim of a previous mass in the right thenar muscle and conglomerated hypermetabolic lesions (SUVmax, 5.3) in the right axillary space. It suggested postoperative inflammation in the right thenar muscle and metastatic lymphadenopathy in the (Fig. 1D) .
On the 3rd hospital day (HD), despite of the repeated blood product transfusions, the massive bleeding from the operation site and the intravenous access site worsened, and a gross hematuria developed. On the 4th HD, the pathologic findings of the mass were reported as alveolar rhabdomyosarcoma with positive immn unohistochemical stains of myognesin, desmin, and MyoD and with negative resection margin. The patient was transferred to the intensive care unit, and chemotherapy consisting of vincristine, doxorubicin, and cyclophosphamide (VAC) was administered. Also, repeated transfusions, synthetic protease inhibitor, and substitu tion of antithrombinIII were administered.
On the 10th HD, a massive epistaxis led to hematemesis of ap proximately 1.5 L of blood, and it required transfusions of 4 units of red blood cells (RBCs), 9 units of platelet concentrates (PCs), 1 unit of fresh frozen plasma (FFP), and 8 units of cryoprecipitate, with two times of cauterization. Two weeks after the chemotherapy was started, the laboratory findings of DIC showed improvement (Fig. 2) , so a BM section biopsy and an axillary LN biopsy were performed. The histologic finding of BM (Fig. 1E ) and axillary LN revealed involvement of rhabdomyosarcoma.
During the initial 20 days of admission, the patient received total blood transfusions of 311 units (26 units of RBC, 26 units of FFP, 74 units of PC, 17 units of single donor platelets, and 168 units of cryoprecipitate) for the control of the DIC and bleeding. On the 28th HD or three weeks after the start of chemotherapy, the patient was discharged.
The patient received a combination chemotherapy consisting of VAC every 3 weeks. At 9th week after the start of chemothe rapy, the size of right axillary LN decreased from 3.6 cm to 2.1 cm. At 21st week after the start of chemotherapy, the BM showed disappearance of rhabodyosarcoma and negative immunostaining for desmin or myogenin. For the planned highdose chemotherapy with autologous peripheral blood stem cell (APBSC) transplanta tion, two rounds of APBSC collections were performed. Unfortu nately, however, at the 27th week of chemotherapy, the patient was found to have a nodule in the right forearm that was increasing in size for over 2 weeks, and the biopsy revealed it as an alveolar rhabdomyosarcoma. Despite of the salvage chemotherapy consis ting of ifosfamide, carboplatin, etoposide, and palliative radiation therapy (right axilla, arm, thenar muscle, and liver, 36 Gy), the patient died 5 months later from the disease progression to the liver and the brain.
Discussion
The solid malignancies are rare causes of DIC, and the mecha nism is unclear. Recent studies show that the solid tumors express different procoagulant molecules including tissue factor (TF), which binds to factor VII(a) to activate the factors IX and X, and to the cancer procoagulant, which is a cysteine protease with factor X activating properties. Alternatively, most tumors induce a hypofi brinolytic state, due to high levels of fibrinolytic inhibitor such as are the most common cause of chronic DIC. However, our case was unusual because of its acute presentation of severe DIC which was very difficult to control. The coagulopathy may be triggered by direct surgical manipulation of the tumor. By surgical trauma to the tumor blood vessels, exposure of the subendothelial TF causes the release of cytokines with their procoagulant activity. This can lead to the complication of acute DIC after the trauma to malignant cells 9, 10) . In our case, early administration of chemotherapy and vigorous supportive care, including repeated transfusions, controlled the massive bleeding and DIC at the initial diagnosis. In conclusion, for the patients with rhabdomyosarcoma complicated with DIC, the early start of systemic chemotherapy to diminish the malig nancy triggered procoagulant activity is important. plasminogen activator inhibitor type 1. Virtually, all pathways that lead to the occurrence of DIC are driven by proinflammatory cytokines, such as interleukin6, interleukin1β, interleukin8, and tumor necrosis factorα 2) . The pediatric patients with rhabdomyosarcoma complicated with DIC at diagnosis are rare. These cases were found in the review 5) of 13 cases, published from 1978 to 2010. Out of 11 pa tients with the involvement of BM, 10 cases in which the patients have re covered from the DIC received multiagent chemotherapy, and the recovery time from the DIC varied from 6 days to after 3 cycles of chemotherapy. Multivariate analysis revealed that the older age, male sex, primary tumor necrosis, and advanced tumor stage are the risk factors for DIC 3) . The prognosis of alveolar rhabdomyosarcoma stage IV with the involvement of BM is very poor, especially in the cases complicated by massive DIC 5) . It is very important to administer chemo therapy early, with the aim of diminishing tumortriggered procoagulant activity. There is a dilemma associated with this practice, because cytotoxic agents may aggravate DIC and may also suppress the BM. However, in an inoperable situation, administration of multi drug chemotherapy revealed to have an immediate beneficial effect, even if a measurable antitumor effect is not observed 6) . In the case reported here, despite of the continuous bleeding at the postoperative site, administration of VAC chemotherapy at 4th HD was undertaken and the DIC showed signs of improvement after the 2nd week of chemotherapy.
In the cancer patients complicated with DIC, once the treatment directed at the primary disorder is initiated, the additional suppor tive therapy may be required in order to correct the coagulation abnormalities. Although the low levels of platelet and coagulation factors may increase the risk of bleeding, the plasma or platelet substitution therapy is not indicated on the basis of the laboratory findings alone, unless an active bleeding is present or the invasive procedures are required 7) . In our patient, the massive bleeding re quired as many as 311 units of blood component replacement (26 units of RBC, 26 units of FFP, 74 units of PC, 17 units of single donor platelets, and 168 units of cryoprecipitate).
Based on the concept that DIC is characterized by systemic acti vation of coagulation, anticoagulant therapy may be a principle approach in therapy. However, the safety and efficacy of this stra tegy in malignancyassociated DIC have never been studied in proper clinical settings 2) . According to an experimental study, he parin therapy showed hopeful results in inhibiting the activation of coagulation in DIC 8) . In the cases with obvious thromboembolic disease or where fibrin deposition predominates, heparin therapy could be considered. However, our patient did not receive heparin therapy and only received repeated transfusions, synthetic protease inhibitor, and substitution of antithrombinIII.
Clinically, DIC in malignancy has a less fulminant course than the types of DIC in sepsis and trauma. Particularly, solid tumors
